Vitalere is investing in an innovation platform focused solely on improving diagnosis of celiac disease.

  • Despite affecting 1% of the population1, celiac disease is a notoriously underdiagnosed and misdiagnosed disease.
  • It it estimated that 83% of individuals with celiac disease are undiagnosed or misdiagnosed with other conditions.2
  • It takes an average of 10 years from the onset of symptoms to diagnose the disease.3
  • Diagnosing celiac disease definitively involves an upper gastrointestinal endoscopy to take a biopsy of the small intestine, while on a gluten-containing diet.

1. Green PH, Cellier C. Celiac Disease. N Engl J Med. 2007;357:1731-1743.

2. Rubio-Tapia A, Ludvigsson JF, Brantner TL, Murray JA, Everhart JE. The prevalence of celiac disease in the United States. Am J Gastroenterol. 2012 Oct;107(10):1538-44; quiz 1537, 1545. doi: 10.1038/ajg.2012.219.

3. Green PH, Stavropoulos SN, Panagi SG, Goldstein SL, McMahon DJ, Absan H. Characteristics of adult celiac disease in the USA: results of a national survey. Am J Gastroenterol. 2001;96:126-131.


Clinical decision support system
for celiac disease

Vitalere is currently developing a clinical decision support system to help guide physicians through the diagnostic process for celiac disease in aims of increasing diagnostic accuracy significantly.


Non-invasive testing
for celiac disease

Vitalere is currently investigating a number of non-invasive testing alternatives for helping diagnose celiac disease by developing new approaches and identifying novel genetic markers.